Safety and immunogenicity of COVID-19 vaccination among liver transplant recipients in China
Qiu-Ju Tian a , b , # , Man Xie c , # , Ji-Tao Wang d , # , Yi Wang e , Bei Zhang f , Jin-Zhen Cai a , b , Xiao-Long Qi g , Wei Rao a , b , ∗
a Division of Hepatology, Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
b Department of Organ Transplantation, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
c Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
d CHESS-COVID-19 Group, Xingtai People’s Hospital, Xingtai 054000, China
e Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
f Department of Immunology, Qingdao University Medical College, Qingdao 266000, China
g CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, China
∗ Corresponding author at: Division of Hepatology, Liver Disease Center, Department of Organ Transplantation, the Affiliated Hospital of Qingdao University, No. 59 Hai’er Road, Laoshan District, Qingdao 266000, China.
E-mail address: qdfy_raowei@126.com (W. Rao).
# Contributed equally.
Abstract：During the ongoing coronavirus disease 2019 (COVID-19) pandemic globally, patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation (LT), and immunosuppressed LT recipients appear to be at increased risk of infections, which leads to an increase in mortality [1–6]. Apart from physical distancing, quarantine and isolation, vaccination is crucial for the restraining of the epidemic and the protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and aggravation of COVID-19 [7,8]. A recent prospective, multicenter, open-label study in China has demonstrated the safety of inactivated whole-virion SARS-CoV-2 vaccines in patients with CLD; however, these patients had decreased response (76.7%-78.9%) to SARS-CoV-2 vaccines compared with healthy subjects (90.3%), which might be associated with the impairment in immunity in the population with CLD [9]. This raises the concern in the safety and immunogenicity of COVID-19 vaccination among LT recipients in China since this population may have more suppressed immunity [8,10,11]. Herein, we preliminary investigated the influence of COVID-19 vaccination on general safety, graft function, host immunogenicity of vaccination among LT recipients in a large transplantation center in China.
引用本文:
. [J]. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 605-608.
Tian QJ, Xie M, Wang JT, Wang Y, Zhang B, Cai JZ, Qi XL, Rao W. Safety and immunogenicity of COVID-19 vaccination among liver transplant recipients in China. Hepatobiliary Pancreat Dis Int, 2022, 21(6): 605-608.
2022, Vol. 21 
